Summary
- McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth.
- The company boasts solid revenue and EPS growth, supported by AI integration, expansion into high-demand sectors like GLP-1 and oncology, and a robust business model.
- Shareholder returns are enhanced by aggressive buyback plans, a 15% dividend hike, and a healthy balance sheet, despite a low 0.6% dividend yield.
- Short-term headwinds like higher tax rates and 2Q25 softness could cause volatility, but the long-term outlook remains positive with an attractive valuation.
BCFC
Introduction
This is a very special article, as I discuss a company I have never covered before. As I have been on Seeking Alpha for almost a decade, that doesn't happen very often.
As some readers may know, I
Comments